A Phase 1 interventional study of ABBV-1162 and Placebo in Healthy Volunteers, sponsored by AbbVie. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1162 in healthy adults.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Participants will receive a single oral dose of ABBV-1162.
Drug: ABBV-1162
Participants will receive a single oral dose of placebo.
Drug: Placebo
Oral
Oral
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 31 days
Maximum Plasma Concentration (Cmax) of ABBV-1162
Cmax of ABBV-1162
Time frame: Up to approximately 3 days
Time to Cmax (Tmax) of ABBV-1162
Time to Cmax (Tmax) of ABBV-1162
Time frame: Up to approximately 3 days
Terminal Phase Elimination Rate Constant (Beta) of ABBV-1162
Beta of ABBV-1162
Time frame: Up to approximately 3 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1162
t1/2 of ABBV-1162
Time frame: Up to approximately 3 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-1162
AUCt of ABBV-1162
Time frame: Up to approximately 3 days
AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-1162
AUCinf of ABBV-1162
Time frame: Up to approximately 3 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.